Abstract
Liver X receptors (LXRs) are important regulators of cholesterol, fatty acid, and glucose homeostasis. LXR agonists are effective for treatment of murine models of atherosclerosis, diabetes, and Alzheimer’s disease. Recently we observed that LXR agonists suppressed proliferation of prostate and breast cancer cells in vitro and treatment of mice with the LXR agonist T0901317 suppressed the growth of prostate tumor xenografts. LXR agonists appear to cause G1 cell cycle arrest in cells by reducing expression of Skp2 and inducing the accumulation of p27Kip. T0901317 induced expression of ATP-binding cassette transporter A1 (ABCA1) and delayed the progression of androgen-dependent human prostate tumor xenografts towards androgen-independency in mice. Phytosterols, the plant equivalent of mammalian cholesterol, have recently been shown to be agonists for LXRs. β-Sitosterol and campesterol, the two most common phytosterols, suppressed proliferation of prostate and breast cancer cells. The anticancer activity of phytosterols may be due to LXR signaling. This review examines the potential use of LXR signaling as a therapeutic target in prostate and other cancers.
Similar content being viewed by others
References
Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., Thun M.J. (2005) Cancer statistics. CA Cancer J. Clin. 55: 10–30
Huggins C., Steven R.E., Hodges C.V. (1941) Studies on prostatic cancer. Arch. Sug. 43: 209–223
Hellerstedt B.A., Pienta K.J. (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 52: 154–179
Sporer A., Brill D.R., Schaffner C.P. (1982) Epoxycholesterols in secretions and tissues of normal, benign, and cancerous human prostate glands. Urology 20: 244–250
Swinnen J.V., Roskams T., Joniau S., Van Poppel H., Oyen R., Baert L., Heyns W., Verhoeven G. (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int. J. Cancer 98: 19–22
Shurbaji M.S., Kalbfleisch J.H., Thurmond T.S. (1996) Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum. Pathol. 27: 917–921
Epstein J.I., Carmichael M., Partin A.W. (1995) OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45: 81–86
Chuu C.-P., Hiipakka R.A., Kokontis J.M., Fukuchi J., Chen R.-Y., Liao S. (2006) Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. 66: 6482–6486
Song C., Hiipakka R.A., Liao S. (2000) Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids 65: 423–427
Song C., Hiipakka R.A., Liao S. (2001) Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis. Steroids 66: 473–479
Zelcer N., Tontonoz P. (2006) Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116: 607–614
Li A.C., Glass C.K. (2004) PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid. Res. 45: 2161–2173
Edwards P.A., Kennedy M.A., Mak P.A. (2002) LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul. Pharmacol. 38: 249–256
Fukuchi J., Kokontis J.M., Hiipakka R.A., Chuu C.-P., Liao S. (2004) Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 64: 7686–7689
Awad A.B., Fink C.S. (2000) Phytosterols as anticancer dietary components: evidence and mechanism of action. J. Nutr. 130: 2127–2130
Plat J., Nichols J.A., Mensink R.P. (2005) Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation. J. Lipid Res. 46: 2468–2476
Apfel R., Benbrook D., Lernhardt E., Ortiz M.A., Salbert G., Pfahl M. (1994) A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell. Biol. 14: 7025–7035
Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., Mangelsdorf D.J. (1995) LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9: 1033–1045
Song C., Kokontis J.M., Hiipakka R.A., Liao S. (1994) Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc. Natl. Acad. Sci. USA 91: 10809–10813
Shinar D.M., Endo N., Rutledge S.J., Vogel R., Rodan G.A., Schmidt A. (1994) NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene 147: 273–276
Teboul M., Enmark E., Li Q., Wikstrom A.C., Pelto-Huikko M., Gustafsson J.A. (1995) OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc. Natl. Acad. Sci. USA 92: 2096–2100
Seol W., Choi H.S., Moore D.D. (1995) Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol. Endocrinol. 9: 72–85
Le Beau M.M., Song C., Davis E.M., Hiipakka R.A., Kokontis J.M., Liao S. (1995) Assignment of the human ubiquitous receptor gene (UNR) to 19q13.3 using fluorescence in situ hybridization. Genomics 26: 166–168
Song C., Hiipakka R.A., Kokontis J.M., Liao S. (1995) Ubiquitous receptor: structures, immunocytochemical localization, and modulation of gene activation by receptors for retinoic acids and thyroid hormones. Ann. NY Acad. Sci. 761: 38–49
Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383: 728–731
Forman B.M., Ruan B., Chen J., Schroepfer G.J. Jr., Evans R.M. (1997) The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl. Acad. Sci. USA 94: 10588–10593
Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., Willson T.M. (1997) Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272: 3137–3140
Song C., Liao S. (2000) Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology 141: 4180–4184
Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., Shan B. (2000) Role of LXRs in control of lipogenesis. Genes Dev. 14: 2831–2838
Collins J.L., Fivush A.M., Watson M.A., Galardi C.M., Lewis M.C., Moore L.B., Parks D.J., Wilson J.G., Tippin T.K., Binz J.G., Plunket K.D., Morgan D.G., Beaudet E.J., Whitney K.D., Kliewer S.A., Willson T.M. (2002) Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 45: 1963–1966
Song C., Liao S. (2001) Hypolipidemic effects of selective liver X receptor alpha agonists. Steroids 66: 673–681
Kaneko E., Matsuda M., Yamada Y., Tachibana Y., Shimomura I., Makishima M. (2003) Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J. Biol. Chem. 278: 36091–36098
Alberti S., Schuster G., Parini P., Feltkamp D., Diczfalusy U., Rudling M., Angelin B., Björkhem I., Pettersson S., Gustafsson J.A. (2001) Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J. Clin. Invest. 107: 565–573
Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.M., Hammer R.E., Mangelsdorf D.J. (1998) Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93: 693–704
Venkateswaran A., Laffitte B.A., Joseph S.B., Mak P.A., Wilpitz D.C., Edwards P.A., Tontonoz P. (2000) Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA 97: 12097–12102
Nakamura K., Kennedy M.A., Baldan A., Bojanic D.D., Lyons K., Edwards P.A. (2004) Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J. Biol. Chem. 279: 45980–45989
Laffitte B.A., Repa J.J., Joseph S.B., Wilpitz D.C., Kast H.R., Mangelsdorf D.J., Tontonoz P. (2001) LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. USA 98: 507–512
Li A.C., Glass C.K. (2004) PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid. Res. 45: 2161–2173
Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N., Tran J., Tippin T.K., Wang X., Lusis A.J., Hsueh W.A., Law R.E., Collins J.L., Willson T.M., Tontonoz P. (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 99: 7604–7609
Blaschke F., Leppanen O., Takata Y., Caglayan E., Liu J., Fishbein M.C., Kappert K., Nakayama K.I., Collins A.R., Fleck E., Hsueh W.A., Law R.E., Bruemmer D. (2004) Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ. Res. 95: e110–e123
Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura L., Shan B., Brown M.S., Goldstein J.L., Mangelsdorf D.J. (2000) Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14: 2819–2830
Yoshikawa T., Shimano H., Amemiya-Kudo M., Yahagi N., Hasty A.H., Matsuzaka T., Okazaki H., Tamura Y., Iizuka Y., Ohashi K., Osuga J., Harada K., Gotoda T., Kimura S., Ishibashi S., Yamada N. (2001) Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 21: 2991–3000
Liang G., Yang J., Horton J.D., Hammer R.E., Goldstein J.L., Brown M.S. (2002) Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J. Biol. Chem. 277: 9520–9528
Tobin K.A., Ulven S.M., Schuster G.U., Steineger H.H., Andresen S.M., Gustafsson J.A., Nebb H.I. (2002) Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis. J. Biol. Chem. 277: 10691–10697
Chen G., Liang G., Ou J., Goldstein J.L., Brown M.S. (2004) Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc. Natl. Acad. Sci. USA 101: 11245–11250
Laffitte B.A., Chao L.C., Li J., Walczak R., Hummasti S., Joseph S.B., Castrillo A., Wilpitz D.C., Mangelsdorf D.J., Collins J.L., Saez E., Tontonoz P. (2003) Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. USA 100: 5419–5424
Efanov A.M., Sewing S., Bokvist K., Gromada J. (2004) Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes 53: S75–S78
Cao G., Liang Y., Broderick C.L., Oldham B.A., Beyer T.P., Schmidt R.J., Zhang Y., Stayrook K.R., Suen C., Otto K.A., Miller A.R., Dai J., Foxworthy P., Gao H., Ryan T.P., Jiang X.C., Burris T.P., Eacho P.I., Etgen G.J. (2003) Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J. Biol. Chem. 278: 1131–1136
Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9: 213–219
Peng D., Song C., Reardon C.A., Liao S., Getz G.S. (2003) Lipoproteins produced by ApoE−/− astrocytes infected with adenovirus expressing human ApoE. J. Neurochem. 86: 1391–1402
Wang L., Schuster G.U., Hultenby K., Zhang Q., Andersson S., Gustafsson J.A. (2002) Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc. Natl. Acad. Sci. USA 99: 13878–13883
Andersson S., Gustafsson N., Warner M., Gustafsson J.A. (2005) Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc. Natl. Acad. Sci. USA 102: 3857–3862
Koldamova R.P., Lefterov I.M., Staufenbiel M., Wolfe D., Huang S., Glorioso J.C., Walter M., Roth M.G., Lazo J.S. (2005) The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer’s disease. J. Biol. Chem. 280: 4079–4088
Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman Z.L., Friedman M., Papsidero L., Kim U., Chai L.S., Kakati S., Arya S.K., Sandberg A.A. (1980) The LNCaP cell line – a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 37: 115–132
Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17: 16–23
Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., Paulson D.F. (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 21: 274–281
Kokontis J., Takakura K., Hay N., Liao S. (1994) Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54: 1566–1573
Kokontis J.M., Hay N., Liao S. (1998) Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol. Endocrinol. 12: 941–953
Kokontis J.M., Hsu S., Chuu C.-P., Dang M., Fukuchi J., Hiipakka R.A., Liao S. (2005) Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 65: 287–298
Umekita Y., Hiipakka R.A., Kokontis J.M., Liao S. (1996) Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc. Natl. Acad. Sci. USA 93: 11802–11807
Chuu C.-P., Hiipakka R.A., Fukuchi J., Kokontis J.M., Liao S. (2005) Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 65: 2082–2084
Linja M.J., Savinainen K.J., Saramaki O.R., Tammela T.L., Vessella R.L., Visakorpi T. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61: 3550–3555
Ford O.H. 3rd, Gregory C.W., Kim D., Smitherman A.B., Mohler J.L. (2003) Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J. Urol. 170: 1817–1821
Fukuchi J., Hiipakka R.A., Kokontis J.M., Hsu S., Ko A.L., Fitzgerald M.L., Liao S. (2004) Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells. Cancer Res. 64: 7682–7685
Fu X., Menke J.G., Chen Y., Zhou G., MacNaul K.L., Wright S.D., Sparrow C.P., Lund E.G. (2001) 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276: 38378–38387
Ettinger S.L., Sobel R., Whitmore T.G., Akbari M., Bradley D.R., Gleave M.E., Nelson C.C. (2004) Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 64: 2212–2221
Heemers H., Maes B., Foufelle F., Heyns W., Verhoeven G., Swinnen J.V. (2001) Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol. Endocrinol. 15: 1817–1828
Oram J.F., Vaughan A.M. (2000) ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr. Opin. Lipidol. 11: 253–260
Freeman M.R., Cinar B., Lu M.L. (2005) Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol. Metab. 16: 273–279
Kim J., Adam R.M., Solomon K.R., Freeman M.R. (2004) Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 145: 613–619
Hazarika P., McCarty M.F., Prieto V.G., George S., Babu D., Koul D., Bar-Eli M., Duvic M. (2004) Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 64: 7361–7369
Bared S.M., Buechler C., Boettcher A., Dayoub R., Sigruener A., Grandl M., Rudolph C., Dada A., Schmitz G. (2004) Association of ABCA1 with syntaxin 13 and flotillin-1 and enhanced phagocytosis in tangier cells. Mol. Biol. Cell 15: 5399–5407
Culig Z., Steiner H., Bartsch G., Hobisch A. (2005) Interleukin-6 regulation of prostate cancer cell growth. J. Cell Biochem. 95: 497–505
Chen T., Wang L.H., Farrar W.L. (2000) Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 60: 2132–2135
Lee S.O., Lou W., Hou M., de Miguel F., Gerber L., Gao A.C. (2003) Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer Res. 9: 370–376
Lee S.O., Lou W., Johnson C.S., Trump D.L., Gao A.C. (2004) Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 60: 178–186
De Stefani E., Boffetta P., Ronco A.L., Brennan P., Deneo-Pellegrini H., Carzoglio J.C., Mendilaharsu M. (2000) Plant sterols and risk of stomach cancer: a case–control study in Uruguay. Nutr. Cancer 37: 140–144
Ronco A., De Stefani E., Boffetta P., Deneo-Pellegrini H., Mendilaharsu M., Leborgne F. (1999) Vegetables, fruits, and related nutrients and risk of breast cancer: a case–control study in Uruguay. Nutr. Cancer 35: 111–119
Mendilaharsu M., De Stefani E., Deneo-Pellegrini H., Carzoglio J., Ronco A. (1998) Phytosterols and risk of lung cancer: a case-control study in Uruguay. Lung Cancer 21: 37–45
McCann S.E., Ambrosone C.B., Moysich K.B., Brasure J., Marshall J.R., Freudenheim J.L., Wilkinson G.S., Graham S. (2005) Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr. Cancer 53: 33–41
Awad A.B., Gan Y., Fink C.S. (2000) Effect of beta-sitosterol, a plant sterol, on growth, protein phosphatase 2A, and phospholipase D in LNCaP cells. Nutr. Cancer 36: 74–78
Awad A.B., Fink C.S., Williams H., Kim U. (2001) In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur. J. Cancer Prev 10: 507–513
Ju Y.H., Clausen L.M., Allred K.F., Almada A.L., Helferich W.G. (2004) Beta-sitosterol, beta-sitosterol glucoside, and a mixture of beta-sitosterol and beta-sitosterol glucoside modulate the growth of estrogen-responsive breast cancer cells in vitro and in ovariectomized athymic mice. J. Nutr. 134: 1145–1151
Awad A.B., Downie A., Fink C.S., Kim U. (2000) Dietary phytosterol inhibits the growth and metastasis of MDA-MB-231 human breast cancer cells grown in SCID mice. Anticancer Res. 20: 821–824
Andersson S.W., Skinner J., Ellegard L., Welch A.A., Bingham S., Mulligan A., Andersson H., Khaw K.T. (2004) Intake of dietary plant sterols is inversely related to serum cholesterol concentration in men and women in the EPIC Norfolk population: a cross-sectional study. Eur. J. Clin. Nutr. 58: 1378–1385
Katan M.B., Grundy S.M., Jones P., Law M., Miettinen T., Paoletti R. (2003) Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin. Proc. 78: 965–978
Plosch T., Kruit J.K., Bloks V.W., Huijkman N.C., Havinga R., Duchateau G.S., Lin Y., Kuipers F. (2006) Reduction of cholesterol absorption by dietary plant sterols and stanols in mice is independent of the Abcg5/8 transporter. J. Nutr. 136: 2135–2140
Yang C., Yu L., Li W., Xu F., Cohen J.C., Hobbs H.H. (2004) Disruption of cholesterol homeostasis by plant sterols. J. Clin. Invest. 114: 813–822
Acknowledgements
This study was supported by the US National Institute of Health grants CA58073 and a fund from Yen Chuang Foundation. We thank Rou-Yu Chen, Karen Warner, and Drs. Junichi Fukuchi, Ching Song, Dacheng Peng, and Stephen Hsu for helpful advice and discussion.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chuu, CP., Kokontis, J.M., Hiipakka, R.A. et al. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J Biomed Sci 14, 543–553 (2007). https://doi.org/10.1007/s11373-007-9160-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11373-007-9160-8